{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T01:08:57Z","timestamp":1793668137646,"version":"4.5.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2020.01.063","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T02:19:21Z","timestamp":1580437161000},"page":"2340-2349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Neutralizing antibodies to gB based CMV vaccine requires full length antigen but reduced virus neutralization on non-fibroblast cells limits vaccine efficacy in the guinea pig model"],"prefix":"10.1016","volume":"38","author":[{"given":"K. Yeon","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9664-0763","authenticated-orcid":false,"given":"Nadia S.","family":"El-Hamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.01.063_b0005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.spid.2004.09.011","article-title":"Congenital cytomegalovirus infection: outcome and diagnosis","volume":"16","author":"Ross","year":"2005","journal-title":"Semin Pediatr Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.063_b0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0065-3527(08)00405-3","article-title":"Rhesus cytomegalovirus a nonhuman primate model for the study of human cytomegalovirus","volume":"72","author":"Yue","year":"2008","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.vaccine.2020.01.063_b0015","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1128\/jvi.55.2.402-409.1985","article-title":"The placenta as a site of cytomegalovirus infection in guinea pigs","volume":"55","author":"Griffith","year":"1985","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.01.063_b0020","unstructured":"Kaufmann P. Guinea Pig Cavia procellus. In: Benirschke KEditorComparitive Placentation http:\/\/medicineucsdedu\/cpa\/guinea\/htm 2004."},{"key":"10.1016\/j.vaccine.2020.01.063_b0025","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.placenta.2007.02.005","article-title":"The Guinea pig placenta: model of placental growth dynamics","volume":"28","author":"Mess","year":"2007","journal-title":"Placenta"},{"key":"10.1016\/j.vaccine.2020.01.063_b0030","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/infdis\/160.6.929","article-title":"Congenital cytomegalovirus labyrinthitis and sensorineural hearing loss in guinea pigs","volume":"160","author":"Woolf","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.063_b0035","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1099\/vir.0.027789-0","article-title":"Re-evaluation of the genome sequence of guinea pig cytomegalovirus","volume":"92","author":"Kanai","year":"2011","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2020.01.063_b0040","series-title":"Cytomegaloviruses: From Molecular Pathogenesis to Intervention","first-page":"88","article-title":"The Guinea Pig Model of Congenital Cytomegalovirus Infection","author":"McGregor","year":"2013"},{"key":"10.1016\/j.vaccine.2020.01.063_b0045","article-title":"Viral glycoprotein complex formation, essential function and immunogenicity in the guinea pig model for cytomegalovirus","volume":"10","author":"Coleman","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.063_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005755","article-title":"A homolog pentameric complex dictates viral epithelial tropism, pathogenicity and congenital infection rate in guinea pig cytomegalovirus","volume":"12","author":"Coleman","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2020.01.063_b0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.virol.2013.03.008","article-title":"Characterization of the guinea pig CMV gH\/gL\/GP129\/GP131\/GP133 complex in infection and spread","volume":"441","author":"Auerbach","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.01.063_b0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virol.2017.06.008","article-title":"Cytomegalovirus UL128 homolog mutants that form a pentameric complex produce virus with impaired epithelial and trophoblast cell tropism and altered pathogenicity in the guinea pig","volume":"509","author":"Coleman","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.01.063_b0065","doi-asserted-by":"crossref","first-page":"7902","DOI":"10.1128\/JVI.00283-16","article-title":"A novel non-replication-competent cytomegalovirus capsid mutant vaccine strategy is effective in reducing congenital infection","volume":"90","author":"Choi","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.01.063_b0070","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1006\/viro.1994.1294","article-title":"Identification of an abundant disulfide-linked complex of glycoproteins in the envelope of guinea pig cytomegalovirus","volume":"201","author":"Britt","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.01.063_b0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0166-0934(02)00258-6","article-title":"Cloning and expression of the guinea pig cytomegalovirus glycoprotein B (gB) in a recombinant baculovirus: utility for vaccine studies for the prevention of experimental infection","volume":"108","author":"Schleiss","year":"2003","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2020.01.063_b0080","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00268-17","article-title":"Progress toward development of a vaccine against congenital cytomegalovirus infection","volume":"24","author":"Schleiss","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.01.063_b0085","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.01.063_b0090","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.01.063_b0095","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1086\/382751","article-title":"Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine","volume":"189","author":"Schleiss","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.063_b0100","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1016\/j.vaccine.2013.04.078","article-title":"Effects of immunization of pregnant guinea pigs with guinea pig cytomegalovirus glycoprotein B on viral spread in the placenta","volume":"31","author":"Hashimoto","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.063_b0105","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.vaccine.2016.03.005","article-title":"Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection","volume":"34","author":"Cardin","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.063_b0110","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1016\/j.vaccine.2015.06.019","volume":"33","author":"Swanson","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.063_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006281","article-title":"Human cytomegalovirus glycoprotein complex gH\/gL\/gO uses PDGFR-alpha as a key for entry","volume":"13","author":"Wu","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2020.01.063_b0120","article-title":"Inclusion of the viral pentamer complex in a vaccine design greatly improves protection against congenital cytomegalovirus in the guinea pig","volume":"93","author":"Choi","year":"2019","journal-title":"Model. J Virol"},{"key":"10.1016\/j.vaccine.2020.01.063_b0125","doi-asserted-by":"crossref","first-page":"E4997","DOI":"10.1073\/pnas.1316517110","article-title":"Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine","volume":"110","author":"Freed","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.01.063_b0130","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02033-16","article-title":"Neutralization of diverse human cytomegalovirus strains conferred by antibodies targeting viral gH\/gL\/pUL128-131 pentameric complex","volume":"91","author":"Ha","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.01.063_b0135","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2008.07.092","article-title":"Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection","volume":"26","author":"Cui","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.063_b0140","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1016\/j.vaccine.2018.07.056","article-title":"Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response","volume":"36","author":"Cui","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.063_b0145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.virusres.2003.12.030","article-title":"Identification of essential and non-essential genes of the guinea pig cytomegalovirus (GPCMV) genome via transposome mutagenesis of an infectious BAC clone","volume":"101","author":"McGregor","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2020.01.063_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005856","article-title":"Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis","volume":"4","author":"Xing","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.063_b0155","first-page":"2212","article-title":"The effect of systemic decomplementation with cobra venom factor on corneal complement levels in guinea pigs","volume":"33","author":"Pleyer","year":"1992","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.vaccine.2020.01.063_b0160","doi-asserted-by":"crossref","first-page":"30422","DOI":"10.18632\/oncotarget.16503","article-title":"The innate immunity of guinea pigs against highly pathogenic avian influenza virus infection","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.vaccine.2020.01.063_b0165","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1099\/vir.0.19508-0","article-title":"Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques","volume":"84","author":"Yue","year":"2003","journal-title":"J General Virol"},{"key":"10.1016\/j.vaccine.2020.01.063_b0170","doi-asserted-by":"crossref","first-page":"14118","DOI":"10.1073\/pnas.0804365105","article-title":"HCMV gH\/gL\/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors","volume":"105","author":"Ryckman","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.01.063_b0175","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1099\/vir.0.064527-0","article-title":"Guinea pig cytomegalovirus GP129\/131\/133, homologues of human cytomegalovirus UL128\/130\/131A, are necessary for infection of monocytes and macrophages","volume":"95","author":"Yamada","year":"2014","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2020.01.063_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001256","article-title":"HCMV spread and cell tropism are determined by distinct virus populations","volume":"7","author":"Scrivano","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2020.01.063_b0185","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1743-422X-5-139","article-title":"Analysis of the nucleotide sequence of the guinea pig cytomegalovirus (GPCMV) genome","volume":"5","author":"Schleiss","year":"2008","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2020.01.063_b0190","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1128\/JVI.79.7.4066-4079.2005","article-title":"Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B","volume":"79","author":"Britt","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.01.063_b0195","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/jvi.64.3.1079-1085.1990","article-title":"Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response","volume":"64","author":"Britt","year":"1990","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.01.063_b0200","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/infdis\/165.2.381","article-title":"Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity","volume":"165","author":"Marshall","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.063_b0205","article-title":"Additive protection against congenital cytomegalovirus conferred by combined glycoprotein B\/pp65 vaccination using a lymphocytic choriomeningitis virus","volume":"24","author":"Schleiss","year":"2017","journal-title":"Vector. Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.01.063_b0210","article-title":"Crystal structure of the human cytomegalovirus glycoprotein B","volume":"11","author":"Burke","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2020.01.063_b0215","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/viro.1996.0424","article-title":"Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells","volume":"222","author":"Boppana","year":"1996","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.01.063_b0220","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1128\/JVI.00883-10","article-title":"Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques","volume":"85","author":"Abel","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.01.063_b0225","doi-asserted-by":"crossref","first-page":"11884","DOI":"10.1128\/JVI.01701-15","article-title":"Vaccine-derived neutralizing antibodies to the human cytomegalovirus gH\/gL pentamer potently block primary cytotrophoblast infection","volume":"89","author":"Chiuppesi","year":"2015","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20301018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20301018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:40:34Z","timestamp":1759401634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20301018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X20301018"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.063","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralizing antibodies to gB based CMV vaccine requires full length antigen but reduced virus neutralization on non-fibroblast cells limits vaccine efficacy in the guinea pig model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}